Equity Clock

Arithmetic Average Seasonal Chart

Geometric Average Seasonal Chart

GYRE Relative to the S&P 500

GYRE Relative to the Sector

% of Revenue Generated in Each Quarter

% of Free Cash Flow Generated in Each Quarter

% of Net Income Generated in Each Quarter

Seasonal Chart Analysis

Analysis of the Gyre Therapeutics, Inc. (NASD:GYRE) seasonal charts above shows that a Buy Date of June 27 and a Sell Date of September 15 has resulted in a geometric average return of 7.24% above the benchmark rate of the S&P 500 Total Return Index over the past 19 years. This seasonal timeframe has shown positive results compared to the benchmark in 11 of those periods. This is a fair rate of success and the return strongly outperforms the relative buy-and-hold performance of the stock over the past 19 years by an average of 39.56% per year.

The seasonal timeframe correlates Poorly with the period of seasonal strength for the Healthcare sector, which runs from April 25 to December 4. The seasonal chart for the broad sector is available via the following link: Healthcare Sector Seasonal Chart.

Gyre Therapeutics, Inc. operates as a biopharmaceutical company. It is focused on the development and commercialization of Hydronidone (F351) for the treatment of Metabolic Dysfunction Associated Steatohepatitis (MASH-associated liver fibrosis). The firm operates through the BC and Gyre segments. The company was founded on March 7, 1997 and is headquartered in San Diego, CA.

To download GYRE seasonal chart data, please log in or Subscribe.

Stocks mentioned in this post: GYRE